冠心病患者皮肤胆固醇与血清胆固醇的相关性研究

来佳成; 韩永生; 汪庆童; 黄崇健; 王玉兰; 朱洋波; 魏小敏; 倪敬书; 董美丽

doi:10.13201/j.issn.1001-1439.2021.10.007

冠心病患者皮肤胆固醇与血清胆固醇的相关性研究

- 1. 安徽医科大学附属省立医院急救医学中心(合肥,230001);
- 2. 中国科学技术大学附属第一医院急救医学中心;
- 3. 安徽医科大学临床药理研究所抗炎免疫药物教育部重点实验室;
- 4. 中国科学院合肥物质科学研究院安徽光学精密机械研究所;
- 5. 中国科学技术大学
基金项目:
国家自然科学基金(No:81973314)

中国科学院科技服务网络计划(STS)区域重点项目(No:KFJ-STS-QYZD-184)

安徽省重点研究与开发计划项目(No:1804 h08020291)

安徽省科技重大专项(No:201903a07020027)

详细信息

通讯作者: 韩永生,E-mail:hanysh1017@163.com

中图分类号: R541.4

收稿日期: 2021-04-08

Association between skin cholesterol and serum cholesterol in patients with coronary heart disease

- 1. Department of Emergency Medicine,Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, 230001, China;
- 2. Department of Emergency Medicine,The First Affiliated Hospital of University of Science and Technology of China;
- 3. Institute of Clinical Pharmacology,Anhui Medical University,Key Laboratory of Anti-Inflammatory and Immune Medicine,Ministry of Education;
- 4. Anhui Institute of Optics and Fine Mechanics,Chinese Academy of Sciences;
- 5. University of Science and Technology of China

More Information

Corresponding author: HAN Yongsheng, E-mail: hanysh1017@163.com

Received Date: 08 April 2021

摘要

摘要: 目的:在冠心病患者随访中应用皮肤胆固醇无创检测系统检测皮肤胆固醇水平,探讨皮肤胆固醇在冠心病慢病管理中的应用价值。方法:本研究为短期、非干预性、前瞻性研究,入选2020年5月—2020年11月在中国科学技术大学附属第一医院住院治疗的急性冠状动脉综合征患者102例,所有患者均采用瑞舒伐他汀10 mg/d作为起始降脂方案,在入院次日、第2周、第4周、第8周、第12周空腹测定血脂及皮肤胆固醇,并根据随访4周时低密度脂蛋白胆固醇(LDL-C)是否达标分为降脂达标组以及降脂未达标组。结果:线性相关分析显示,皮肤胆固醇降幅与LDL-C降幅呈正相关(r=0.528,P<0.001)。在同一随访节点,降脂达标组皮肤胆固醇降幅中位数较未达标组高(P<0.05)。降脂达标组皮肤胆固醇降幅随时间延长逐渐上升,LDL-C降幅总体呈上升趋势;降脂未达标组皮肤胆固醇降幅、LDL-C降幅随时间延长上升不明显。结论:急性冠状动脉综合征患者皮肤胆固醇降幅与血清LDL-C降幅呈正相关,提示皮肤胆固醇在急性冠状动脉综合征慢性期管理中的潜在应用能力。
- 冠状动脉综合征,急性 /
- 皮肤胆固醇 /
- 慢病管理
Abstract: Objective: To investigate the application value of skin cholesterol in chronic disease management of patients with coronary heart disease, and the skin cholesterol was detected using non-invasive skin cholesterol detection system.Methods: A total of 102 patients with acute coronary syndrome, who received rosuvastatin 10 mg/d starting treatment in the First Affiliated Hospital of USTC from May 2020 to November 2020 were included in this short term, prospective, and non-interventional study. Rosuvastatin 10 mg/d was used as the initial lipid-lowering therapy in all patients, serum lipids and skin cholesterol were measured on the day after admission, 2 weeks, 4 weeks, 8 weeks, and 12 weeks after lipid-lowering treatment. According to the low-density lipoprotein cholesterol(LDL-C) level at 4 weeks of follow-up, all patients were divided into the standard lipid-lowering group and the substandard lipid-lowering group.Results: Linear correlation analysis showed that the reduction of skin cholesterol was positively correlated with the reduction of LDL-C(r = 0.528, P < 0.001). At the same follow-up point, the median reduction of skin cholesterol in the standard lipid-lowering group was higher than that in the substandard lipid-lowering group(P < 0.05). In the standard lipid-lowering group, the reduction of skin cholesterol increased gradually with time, and the reduction of LDL-C showed an overall upward trend. The reduction of skin cholesterol and LDL-C in the substandard lipid-lowering group did not increase significantly over time.Conclusion: The reduction of skin cholesterol is positively correlated with the reduction of serum LDL-C in patients with acute coronary syndrome. Skin cholesterol has potential value in the clinical application of chronic disease management in patients with acute coronary syndrome.
- acute coronary syndrome /
- skin cholesterol /
- chronic disease management

HTML全文

参考文献(16)

[1]	Abajobir AA,Abate KH,Abbafati C,et al.Global,Regional,and national comparative risk assessment of 84 behavioural,environmental and occupational,and metabolic risks or clusters of risks,1990-2016:asystematic analysis for the global burden of disease study 2016[J].Lancet,2017,390(10100):1345-1422.
[2]	Zhou M,Wang H,Zeng X,et al.Mortality,morbidity,and risk factors in China and its provinces,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2019,394(10204):1145-1158.
[3]	Alenghat FJ,Davis AM.Management of blood cholesterol[J].JAMA,2019,321(8):800-801.
[4]	中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华心血管病杂志,2016,44(10):833-853.
[5]	Grundy SM,Stone NJ,Bailey AL,et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].Circulation,2019,139(25):e1082-e1143.
[6]	Hu H,Gao Y,Tang J,et al.Effect of a high-cholesterol diet on lipoprotein metabolism and xanthoma formation in rabbits[J].J Cosmet Dermatol,2018,17(5):885-888.
[7]	Mancini GB,Chan S,Frohlich J,et al.Association of skin cholesterol content,measured by a noninvasive method,with markers of inflammation and Framingham risk prediction[J].Am J Cardiol,2002,89(11):1313-1316.
[8]	Tzou WS,Mays ME,Korcarz CE,et al.Skin cholesterol content identifies increased carotid intima-media thickness in asymptomatic adults[J].Am Heart J,2005,150(6):1135-1139.
[9]	Vaidya D,Ding J,Hill JG,et al.Skin tissue cholesterol assay correlates with presence of coronary calcium[J].Atherosclerosis,2005,181(1):167-173.
[10]	Sprecher DL,Pearce GL.Elevated skin tissue cholesterol levels and myocardial infarction[J].Atherosclerosis,2005,181(2):371-373.
[11]	Stein JH,Tzou WS,DeCara JM,et al.Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk(from the Predictor of Advanced Subclinical Atherosclerosis study)[J].Am J Cardiol,2008,101(7):986-991.
[12]	候华毅,董美丽,王贻坤,等.漫反射光谱技术快速无创检测皮肤胆固醇[J].光谱学与光谱分析,2016,36(10):3215-3221.
[13]	候华毅,方朝晖,张元志,等.皮肤胆固醇无创光谱检测模拟和在体实验研究[J].中国激光,2016,43(9):907001.
[14]	吴鹏,倪敬书,洪海鸥,等.基于荧光光谱法的皮肤胆固醇快速无创检测技术[J].中国激光,2021,48(3):104-112.
[15]	陈伟伟,高润霖,刘力生,等.《中国心血管病报告_2017》概要[J].中国循环杂志,2018,33(1):1-8.
[16]	Stone GW,Maehara A,Lansky AJ,et al.A prospective natural-history study of coronary atherosclerosis[J].N Engl J Med,2011,364(3):226-235.